Armata achieved a major milestone with positive topline results from its Phase 1b/2a clinical trial of AP-SA02 for Staphylococcus aureus bacteremia. These 10 stocks could mint the next wave of ...

Entered into secured credit agreement with Innoviva for $15 million maturing in 2029 Announced positive topline results from the Phase 1b /2a diSArm trial for AP-SA02 ...